中国组织工程研究 ›› 2014, Vol. 18 ›› Issue (49): 8001-8006.doi: 10.3969/j.issn.2095-4344.2014.49.023

• 器官移植动物模型 organ transplantation and animal model • 上一篇    下一篇

慢性胰腺炎模型大鼠转化生长因子β1/Smads通路被秋水仙碱的抑制

陆宏伟,张亚飞,吉 鸿,王晋龙,黎一鸣   

  1. 西安交通大学医学院第二附属医院普通外科,陕西省西安市 710004
  • 修回日期:2014-09-19 出版日期:2014-11-30 发布日期:2014-11-30
  • 通讯作者: 黎一鸣,教授,博士生导师,西安交通大学医学院第二附属医院普通外科,陕西省西安市 710004
  • 作者简介:陆宏伟,男,1974年生,陕西省宝鸡市人,博士,副主任医师,主要从事肝胆胰脾方面的研究。
  • 基金资助:

    陕西省社发攻关项目(2007k14-02(17))

Inhibitory effect of colchicine on transforming growth factor β1/Smads pathway in rat models of chronic pancreatitis   

Lu Hong-wei, Zhang Ya-fei, Ji Hong, Wang Jin-long, Li Yi-ming   

  1. Department of General Surgery, Second Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China
  • Revised:2014-09-19 Online:2014-11-30 Published:2014-11-30
  • Contact: Li Yi-ming, Professor, Doctoral supervisor, Department of General Surgery, Second Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China
  • About author:Lu Hong-wei, M.D., Associate chief physician, Department of General Surgery, Second Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China
  • Supported by:

    the Research Project of Social Development in Shaanxi Province of China, No. 2007k14-02(17)

摘要:

背景:胰腺星状细胞内转化生长因子β1/Smads信号通路活化可能是导致胰腺组织纤维化的主要分子学机制。如能阻断这一通路,就可能抑制慢性胰腺炎组织的纤维化进程。

目的:探讨秋水仙碱对慢性胰腺炎模型大鼠转化生长因子β1/Smads通路的抑制作用。
方法:健康雄性SD大鼠随机分为慢性胰腺炎组及秋水仙碱干预组,慢性胰腺炎造模成功后,秋水仙碱干预组大鼠每日腹腔内注射秋水仙碱150 μg/ kg,慢性胰腺炎组则每日腹腔内注射等体积的生理盐水。3个月后取胰腺组织,苏木精-伊红染色观察胰腺组织的病理学改变,免疫组化观察胰腺组织转化生长因子β1表达,Western blot 法测定胰腺星形细胞内P-Smad2、P-Smad3、α-SMA蛋白表达水平。
结果与结论:苏木精-伊红染色结果显示:与秋水仙碱干预组相比,慢性胰腺炎组胰腺组织内腺体组织减少,而纤维结缔组织、炎细胞明显增多并取代胰腺腺体组织。免疫组化结果显示:秋水仙碱干预组胰腺组织内转化生长因子β1阳性表达级别和阳性细胞指数显著低于慢性胰腺炎组(P < 0.05)。Western blot 结果显示:慢性胰腺炎组胰腺星形细胞内P-Smad2/β-actin、P-Smad3/β-actin、α-SMA/β-actin表达明显低于秋水仙碱干预组(P < 0.05)。结果提示秋水仙碱可以抑制慢性胰腺炎大鼠转化生长因子β1/Smads信号通路及胰腺组织纤维化。因此,秋水仙碱可作为治疗慢性胰腺炎纤维化的一种新的候选方案。


中国组织工程研究
杂志出版内容重点:肾移植肝移植移植;心脏移植;组织移植;皮肤移植;皮瓣移植;血管移植;器官移植组织工程


全文链接:

关键词: 实验动物, 组织工程, 转化生长因子β1, P-Smad2, P-Smad 3, α-SMA, 慢性胰腺炎

Abstract:

BACKGROUND: Pancreatic stellate cells transforming growth factor β1/Smads signaling pathway activation is probably a main molecular mechanism of pancreatic fibrosis. If this pathway can be blocked, the progression of fibrosis of tissues with chronic pancreatitis will be inhibited.

OBJECTIVE: To study the inhibitory effect of colchicine on transforming growth factor β1/Smads pathway in chronic pancreatitis rat models.
METHODS: Healthy male Sprague-Dawley rats were randomly divided into colchicines-treated group and chronic pancreatitis group. After successful establishment of rat models of chronic pancreatitis, the rats in the colchicines-treated group were intraperitoneally injected with colchicine 150 μg/kg daily. The rats in the chronic pancreatitis group were intraperitoneally injected with equal volume of physiological saline daily. Pancreatic tissues were collected after 3 months. Hematoxylin-eosin staining was used to observe histopathological changes of pancreatic tissue. Immunohistochemical staining was used to detect the expressions of transforming growth factor β1 in pancreatic tissue. Western blot assay was utilized to detect the expressions of P-Smad2, P-Smad3 and α-SMA protein in pancreatic stellate cells.
RESULTS AND CONCLUSION: Hematoxylin-eosin staining results revealed that compared with the colchicines-treated group, glandular tissue had reduced, while fibrous connective tissue and inflammatory cells had increased obviously and replaced the pancreatic gland tissue in the chronic pancreatitis group. Immunohistochemical staining results demonstrated that the expression levels of transforming growth factor β1 and the index of positive cells were significantly lower in the colchicines-treated group than those in the chronic pancreatitis group (P < 0.05). Western blot assay results revealed that the results of P-Smad2/β-actin, P-Smad3/β-actin and α-SMA/β-actin in pancreatic stellate cells were significantly lower in the chronic pancreatitis group than those in the colchicines-treated group (P < 0.05). Results suggested that colchicine could inhibit the activity of transforming growth factor β1/Smads pathway and pancreatic tissue fibrosis in chronic pancreatitis rats. Therefore, colchicine can be used as a new candidate therapeutic scheme for chronic pancreatitis fibrosis.


中国组织工程研究
杂志出版内容重点:肾移植肝移植移植;心脏移植;组织移植;皮肤移植;皮瓣移植;血管移植;器官移植组织工程


全文链接:

Key words: transforming growth factor beta 1, smad2 protein, smad3 protein, pancreatitis, chronic

中图分类号: